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BACKGROUND
Cortical-bone fragility is a common feature in osteoporosis that is linked to non-
vertebral fractures. Regulation of cortical-bone homeostasis has proved elusive. The 
study of genetic disorders of the skeleton can yield insights that fuel experimental 
therapeutic approaches to the treatment of rare disorders and common skeletal 
ailments.
METHODS
We evaluated four patients with Pyle’s disease, a genetic disorder that is characterized 
by cortical-bone thinning, limb deformity, and fractures; two patients were examined 
by means of exome sequencing, and two were examined by means of Sanger se-
quencing. After a candidate gene was identified, we generated a knockout mouse 
model that manifested the phenotype and studied the mechanisms responsible for 
altered bone architecture.
RESULTS
In all affected patients, we found biallelic truncating mutations in SFRP4, the gene 
encoding secreted frizzled-related protein 4, a soluble Wnt inhibitor. Mice deficient 
in Sfrp4, like persons with Pyle’s disease, have increased amounts of trabecular bone 
and unusually thin cortical bone, as a result of differential regulation of Wnt and 
bone morphogenetic protein (BMP) signaling in these two bone compartments. Treat-
ment of Sfrp4-deficient mice with a soluble Bmp2 receptor (RAP-661) or with anti-
bodies to sclerostin corrected the cortical-bone defect.
CONCLUSIONS
Our study showed that Pyle’s disease was caused by a deficiency of sFRP4, that cortical-
bone and trabecular-bone homeostasis were governed by different mechanisms, and 
that sFRP4-mediated cross-regulation between Wnt and BMP signaling was critical 
for achieving proper cortical-bone thickness and stability. (Funded by the Swiss Na-
tional Foundation and the National Institutes of Health.)
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O
steoporosis is a skeletal disease 
that is characterized by low bone mass, 
defective bone structure, and a high risk 
of fracture. Cortical-bone mass is a major deter-
minant of bone strength and therefore of suscep-
tibility to fractures. With aging, the mass of corti-
cal bone may decrease more than the mass of 
trabecular bone, and fractures occurring in older 
persons result mostly from cortical-bone fragility. 
Although progress has been made in therapeutic 
approaches to reducing the risk of vertebral frac-
ture (which occurs at sites rich in trabecular bone), 
currently available treatments do little to reduce 
the risk of nonvertebral fracture, which results 
mostly from cortical-bone fragility.1-3
Pyle’s disease (Online Mendelian Inheritance in 
Man [OMIM] number, 265900) was described 
in 1931 by Edwin Pyle, an orthopedic surgeon in 
Connecticut, as a “case of unusual bone develop-
ment”; it was described again in 1933, by the 
German radiologist Max Cohn, as “spongious hy-
pertrophy of bone.” Pyle’s disease is characterized 
by long bones with wide and expanded trabecular 
metaphyses, thin cortical bone, and bone fragil-
ity.4-7 Fractures are common in Pyle’s disease, and 
fracture lines usually go through the abnormally 
wide metaphyses, revealing their fragility. We con-
sidered that unlike other mendelian disorders that 
affect overall bone density,8 Pyle’s disease seems 
to be a disorder of bone architecture, and an un-
derstanding of its pathogenesis might offer in-
sights into cortical-bone homeostasis.
We evaluated four patients with Pyle’s disease, 
by means of exome sequencing or Sanger sequenc-
ing, to identify the genetic basis for the disorder. 
After a candidate causal gene was identified, we 
studied a knockout mouse model to determine 
the role of the gene in the pathogenesis of Pyle’s 
disease, in skeletal development and homeostasis, 
and in determining the strength of trabecular 
and cortical bone, as well as to test methods of 
treatment.
Me thods
Patients
Patients 1 and 2 were a brother and sister who 
were referred for skeletal deformity at 16 and 14 
years of age, respectively. The parents were first-
degree cousins originating from Turkey; they were 
healthy and of normal height. The motor and 
mental development of Patient 1 were normal, 
and his height was in the upper range of normal. 
Tooth eruption was delayed, starting at the age 
of 1 year and finishing only at 7 years of age. 
The deciduous teeth failed to shed. Genu valgum 
was noted when the patient was 7 years of age 
and was progressive. No pain or muscular weak-
ness was reported. He had two fractures after 
minimal trauma: the left radius at 7 years of age 
and the right femur at 17 years of age after or-
thopedic surgery for valgus correction. At 16 years 
of age, his height was 177 cm (75th percentile), 
his weight 60 kg (25th to 50th percentile), his head 
circumference 52 cm (>2 SD below the mean for 
his age), and his arm span 181 cm. A radiograph-
ic survey showed disturbed modeling of the long 
bones, with wide metaphyses and thin cortexes, 
and an absence of paranasal sinuses — findings 
consistent with Pyle’s disease (Fig. 1A and 1B).4,6 
Bone mineral densitometry (conducted by means 
of fan beam dual-energy x-ray absorptiometry 
[DXA] on a GE Lunar Prodigy machine) of the 
lumbar spine (L1 to L4) and proximal femur re-
vealed z scores of −2.7 and −1.1, respectively. 
The levels of calcium, phosphate, alkaline phos-
phatase, vitamin D, and parathyroid hormone in 
plasma or serum were normal (Table S1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org).
Patient 2, the younger sister of Patient 1, had 
dental findings similar to those of her brother. 
She did not have bone fractures, walking difficulty, 
joint pain, or muscular weakness. At 14 years of 
age, her height was 172 cm (>97th percentile), 
her weight 51 kg (50th percentile), her head cir-
cumference 50 cm (>2 SD below the mean for 
her age), and her arm span 172 cm. She had genu 
valgum, bilateral cubitus valgus, and limitation of 
extension in proximal interphalangeal joints of 
the second, third, fourth, and fifth fingers. The 
radiographic findings were similar to those in 
her elder brother and were consistent with Pyle’s 
disease (Fig. S1 in the Supplementary Appendix).4,6 
Bone mineral densitometry of the lumbar spine 
(L1 to L4) and proximal femur revealed z scores of 
−2.1 and −1.4, respectively. The serum levels of 
calcium, phosphate, alkaline phosphatase, vita-
min D, and parathyroid hormone were normal; 
levels of bone metabolism markers are shown in 
Table S1 in the Supplementary Appendix.
The unaffected parents of Patients 1 and 2 and 
an unaffected younger brother consented to un-
dergo a clinical and radiographic workup. The re-
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Figure 1. Clinical, Radiographic, and Molecular Findings.
Panel A shows Patient 1 at 16 years of age; he had deformation of the lower limbs with marked valgus of both legs. The expanded distal 
femora could be easily palpated above the knees. Panel B is a radiograph of the lower limbs in Patient 1, showing expanded metaphyses 
of the distal femora and proximal and distal tibiae with extremely thin cortexes. The appearance of the bone at the tibial midshaft, with 
thicker cortex, is relatively normal. Panel C is an anteroposterior skull radiograph of Patient 2, showing expansion of the diploe. Panel D 
is an anteroposterior and lateral projection of the distal right tibia in Patient 3, showing changes similar to those in Panel B. In addition, 
two fractures run through the abnormal metaphysis, and a third fracture runs through the distal fibula. Panel E is a hand radiograph of 
Patient 2 at 14 years of age, showing expanded metaphyses and thin cortexes at the distal radius, as well as expansion of the distal metacar-
pals and (to a lesser degree) of the phalanges. Panels F, G, and H show the nucleotide sequences of SFRP4 in controls, affected patients, 
and heterozygous family members. Patients 1 and 2 are homozygous for a nucleotide insertion in exon 2 (Panel F); as a result, amino acid 
residues 167 and 168 are replaced, and a stop codon is generated at position 169, leading to a truncated protein. Both parents and the 
brother are heterozygous for the insertion. Circles denote female family members, squares male family members, open symbols unaffected 
family members, and black symbols affected family members. Patient 3 is homozygous for a C-to-T transition that transforms codon 232 
from arginine to a stop codon (Panel G). Patient 4 is homozygous for the deletion of 7 nucleotides; as a consequence, there is a stretch of 
10 missense amino acids (codons 161–170), followed by a premature termination at codon 171 (Panel H). Panel I is a diagram of the sFRP4 
protein, illustrating the two main domains as well as the positions of the three mutations found in the patients.
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sults of routine blood chemical tests were normal; 
levels of bone metabolism markers were also 
within age-specific reference ranges (Table S1 in 
the Supplementary Appendix). Skeletal radiographs 
showed a mild tubulation defect of the long bones, 
as has been observed previously in obligate het-
erozygotes for Pyle’s disease (Fig. S2 in the Sup-
plementary Appendix).4,6
Patient 3 was a 58-year-old man who was evalu-
ated for a possible fracture after a workplace acci-
dent. His height was 173 cm, and his weight was 
72 kg; both measures were between the 50th and 
the 75th percentile for Japanese men. He was from 
Kyushu island, a region with a relatively high level 
of consanguinity. No details of his early medical 
history are known. Fractures were noted in the 
tibia, but the tibia also had a highly abnormal 
shape and structure that prompted additional 
radiographic evaluation. The findings were con-
sidered typical for Pyle’s disease (Fig. 1D, and 
Fig. S1 in the Supplementary Appendix).4,6
Patient 4 was a boy from India. His biologic 
parents were unknown. He was examined at the 
age of 3 years 6 months because of progressive 
genu valgus deformity that had developed after he 
started walking. Apart from the leg deformity, he 
was in good health; his height was in the 10th 
percentile, and there was no history of fractures. 
His primary dentition looked normal. Radiographs 
showed the metaphyseal tubulation defect, chalk-
like appearance of the bone, and lack of cortical 
bone that are typical of Pyle’s disease (Fig. S1 in 
the Supplementary Appendix).4,6
Oversight and Laboratory Studies
Informed consent was obtained from the patients, 
their parents, or both with the use of the con-
sent forms of the Hacettepe University Hospital 
(Ankara, Turkey), the Manipal University Hospi-
tal (Manipal, India), or the Lausanne University 
Hospital (Lausanne, Switzerland). The genetic 
study was conducted with the approval of the 
ethics commission of the Lausanne University 
Hospital. In brief, we sequenced the exomes of 
Patients 1 and 2; in addition, the exons of SFRP4 
in Patients 3 and 4 were sequenced by means of 
Sanger sequencing. Details of the laboratory pro-
cedures, bioinformatics filtering, and prioritiza-
tion of variants are provided in the Supplemen-
tary Appendix. We did not include any other 
patients with Pyle’s disease in the analysis.
We obtained two independent lines of knock-
out mice, one from Procter & Gamble and one 
from Lexicon; both lines had disruption of the 
first exon of Sfrp4 and had the same phenotype. 
Full details regarding the generation of mouse 
models, skeletal phenotyping, ex vivo and in vitro 
studies, and in vivo treatment with the bone mor-
phogenetic protein (BMP) inhibitor, RAP-661, and 
sclerostin antibodies are provided in the Supple-
mentary Appendix.
R esult s
Identification of SFRP4 Mutations
Filtering of the exome-sequencing data from Pa-
tients 1 and 2 (Table S2 in the Supplementary 
Appendix) resulted in the retention of three 
homozygous variants: one in the complement 
component 9 gene (C9), one in DAB2, and a single-
nucleotide insertion predicted to result in a frame-
shift with a premature stop codon (c.498_499insG; 
p.Asp167Glyfs*3) in SFRP4, the gene encoding 
secreted frizzled-related protein 4 (sFRP4) (Fig. 1F 
and 1I). The SFRP4 variant stood out because it af-
fects a protein involved in a pathway that is highly 
relevant to bone homeostasis — that is, the Wnt-
signaling pathway.9 SFRP4 polymorphisms had 
been linked to bone mineral density in genome-
wide association studies,10-13 and SFRP4 had been 
suggested as a candidate gene for craniotubular 
disorders, although no pathogenic mutation had 
been identified.14 Segregation analysis confirmed 
heterozygosity in both parents and in the unaf-
fected brother.
In Patient 3, Sanger sequencing of SFRP4 in 
genomic DNA revealed homozygosity for a differ-
ent point mutation (c.694C→T; p.Arg232*) that 
was predicted to result in a premature stop co-
don with truncation of the protein (Fig. 1G and 
1I). In Patient 4, we found a homozygous dele-
tion of seven nucleotides (c.481_487delGTACAGG; 
p.Val161Lysfs*11) that was predicted to result in 
a short stretch of 10 missense amino acids fol-
lowed by a premature stop codon (Fig. 1H); the 
predicted effect of this mutation at the messen-
ger RNA (mRNA) level was remarkably similar 
to that of the mutation that was found in Pa-
tients 1 and 2. Thus, the observed mutations in 
all four patients were predicted to result in pre-
mature stop codons with truncation of the 
sFRP4 protein. These mutations could result in 
either nonsense-mediated mRNA decay or, if the 
mRNA were translated, the synthesis of a pro-
n engl j med 374;26 nejm.org June 30, 2016 2557
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tein lacking a large portion of the netrin-like do-
main, which is necessary for positioning of sFRP415 
and for Wnt inhibition.16 Quantitative polymerase-
chain-reaction analysis of fibroblast mRNA from 
Patient 2 revealed a severe reduction in SFRP4 
mRNA (Fig. S3 in the Supplementary Appendix), 
which suggests that the c.498_499insG mutation 
results in nonsense-mediated mRNA decay.
Markers of Bone Turnover
We assayed plasma levels of osteocalcin, procol-
lagen type 1 N-terminal propeptide (P1NP), and 
bone-specific alkaline phosphatase as markers of 
bone formation, carboxy-terminal collagen cross-
links as a marker of bone resorption, and osteo-
protegerin and sclerostin in all members of Fam-
ily 1 (Table S1 in the Supplementary Appendix). 
The P1NP levels exceeded those of age-related and 
puberty-related control values in both affected 
family members, possibly resulting from an in-
creased rate of type I collagen synthesis and de-
position. Osteocalcin levels were also higher than 
reference values. The levels of bone-specific alka-
line phosphatase were elevated in both affected 
family members and in the heterozygous brother. 
Together, the three osteoblast-derived metabolites 
seem to indicate a particularly active bone deposi-
tion process. The levels of carboxy-terminal col-
lagen crosslinks were normal, which suggested 
a normal bone resorption rate at the systemic level. 
Levels of osteoprotegerin and sclerostin were also 
in the normal ranges.
Bone Findings in Mice Lacking Sfrp4
In Sfrp4-null mice (Fig. S4A, S4B, and S4C in the 
Supplementary Appendix), levels of systemic bone 
markers were not substantially altered, and serum 
levels of calcium, phosphate, and 1,25-dihydroxy-
vitamin D were normal,17 despite substantial and 
diametrically opposed changes in cortical bone 
versus trabecular bone. Radiographs (Fig. 2A) 
showed expanded metaphyses with thin cortical 
bone in femora and tibiae when the mice were 
as young as 2 weeks of age — changes that were 
remarkably similar to those observed in the pa-
tients (Fig. 1). Microcomputed tomography analy-
sis of femora from Sfrp4-null mice confirmed the 
presence of thin cortexes, as compared with those 
of wild-type littermates (Fig. 2B); thin cortical 
bone was also found in the calvaria, indicating 
that the cortex in long bones and in the calvaria 
are equally affected by the absence of Sfrp4. His-
tologic examination of 10-week-old mice revealed 
expanded metaphyses surrounded by thin cortexes 
(Fig. 2C). Histomorphometric analysis confirmed a 
disturbed microarchitecture of the skeleton, in 
homozygous mice and in heterozygous mice: 
specifically, there was a gene dosage–dependent 
increase in trabecular-bone volume and bone-
formation rates (Fig. 2C) in addition to a gene 
dosage–dependent reduction in cortical-bone 
thickness in long bones (Fig. 2C). This was ac-
companied by a reduction in mechanical strength 
measured at the diaphysis. The rates of perios-
teal and endocortical mineral apposition were 
equally reduced in adult mice, whereas the width 
of the bones at midshaft was increased (Fig. 2C). 
Altogether, these results suggest that the absence 
of Sfrp4 led to increased trabecular bone, reduced 
cortical-bone thickness, and failure of bone mod-
eling during growth, resulting in wider bones 
with thinner and mechanically inadequate cor-
texes. The findings are similar to those in Pyle’s 
disease and confirm a pathophysiological mech-
anism involving vigorous formation of trabecu-
lar bone but an impairment in the formation of 
cortical bone. Additional radiographs of humans 
and mice and other details on the bone findings 
are provided in Figures S1, S2, S4, and S5 and 
Table S3 in the Supplementary Appendix.
Osteoblast, Osteoclasts, and Sfrp4 Deficiency
The protein sFrp4 is a soluble Wnt decoy recep-
tor that binds Wnt ligands and thus modulates 
both canonical (i.e., β-catenin–dependent) and 
noncanonical (i.e., β-catenin–independent) Wnt 
signaling.15,19 To understand the effects of Sfrp4 
deficiency on cortical and trabecular bone, we 
first sought to determine whether the activation 
state of the Wnt-signaling pathway differs between 
these two compartments. Given that Sfrp4-null 
long-bone cortex and calvariae have the same phe-
notype (decreased thickness), we used primary 
calvarial osteoblasts to investigate the molecular 
mechanisms by which Sfrp4 modulates cortical 
bone. Similarly, because trabecular bone is inti-
mately associated with the bone marrow com-
partment, we used bone marrow–derived osteo-
blasts to assess the effect of Sfrp4 deficiency on 
trabecular bone. Sfrp4-null calvarial osteoblasts 
had activation of both canonical and noncanoni-
cal Wnt signaling, as indicated by an increase in 
active β-catenin and phosphorylated Jnk levels 
and by an increase in the expression of the ca-
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nonical Wnt target gene Axin2; in contrast, Sfrp4 
deficiency led to activation of canonical Wnt sig-
naling but not of noncanonical Wnt signaling in 
bone marrow–derived osteoblasts (Fig. 2D, and 
Fig. S6A in the Supplementary Appendix). This 
difference suggested that the reduced cortical 
bone thickness might result from activation of 
noncanonical Wnt signaling.
Expression of sclerostin, an osteocyte-derived 
potent Wnt inhibitor,20-23 was markedly increased 
in Sfrp4-null calvarial osteoblasts but only mildly 
increased in bone marrow–derived osteoblasts 
(Fig. 2E), which suggests a possible explanation 
for this differential effect. The sclerostin gene, Sost, 
is a known target of the BMP signaling pathway,24 
and activation of BMP signaling has been shown 
to lead to thin bone cortex.25 Therefore, we sought 
to determine whether changes in BMP expression, 
BMP signaling, or both in response to activated 
noncanonical Wnt signaling might be contribut-
ing to the cortical phenotype in Sfrp4-null mice. 
Activation of noncanonical signaling by Wnt5a 
in the osteoblast cell line MC3T3-E1 increased 
Bmp2 mRNA expression (Fig. 2F); this effect was 
blocked by the addition of sFrp4 (Fig. 2F) and 
enhanced in the absence of Sfrp4 (Fig. 2G). In 
addition, sFrp4 inhibited the Wnt5a-dependent ac-
tivation of the BMP-responsive Id–luc reporter gene, 
as did Noggin and RAP-661, both of which are 
inhibitors of BMP signaling (Fig. S6B in the Sup-
Figure 2 (facing page). Functional Consequences of Sfrp4 Deletion and Correction of the Cortical Phenotype  
in Sfrp4-Null Mice.
Panel A shows representative radiographic images of wild-type and Sfrp4-null female littermates at 10 weeks of age. 
The arrowhead indicates the expanded metaphyses in the Sfrp4-null mice (four mice were analyzed in each geno-
type). Panel B shows microcomputed tomography (microCT) analysis of cortical thickness in femur midshaft of 
wild-type (black bars) and Sfrp4-null (open bars) mice at 4, 7, 17, 24, 60, and 68 weeks of age. The bars show mean 
values; T bars indicate standard errors. P<0.05 for the comparison with wild-type at each time point (five mice were 
analyzed in each genotype). Panel C shows representative histologic features of von Kossa–stained trabecular bone 
in proximal tibiae (top row; scale bar, 1 mm) and cortical bone in the tibial midshaft region (bottom two rows; scale 
bars, 300 μm) of wild-type, heterozygous, and Sfrp4-null mice at 10 weeks of age (five mice were analyzed in each 
genotype). Sfrp4 deletion leads to increased trabecular bone, decreased cortical thickness, and increased width. 
Panel D shows the differential effects of Sfrp4 deletion on canonical and noncanonical Wnt signaling in calvarial os-
teoblasts and bone marrow–derived osteoblasts. The total amount of active β-catenin, phosphorylated Jnk (p-Jnk), 
and total Jnk was assessed in calvarial osteoblasts and bone marrow–derived osteoblasts isolated from Sfrp4-null 
and wild-type littermates. Actin was used as a loading control. Fold differences in protein levels were measured by 
normalizing to actin and to total Jnk and dividing the normalized protein level by the mean normalized level in wild-
type cells; values are expressed as means (±SD). An asterisk indicates P<0.05 for the comparison with wild type 
(three to five independent experiments were performed). Panel E shows the analysis of Sost mRNA expression in 
wild-type and Sfrp4-null calvarial osteoblasts and bone marrow–derived osteoblasts after 0, 14, and 28 days of os-
teogenic differentiation. Sfrp4 deletion affects Sost expression only in calvarial osteoblasts. The bars show mean 
values; T bars indicate standard deviations. An asterisk indicates P<0.05, and a double asterisk P<0.01 for the com-
parison with wild type at each time point (three independent experiments were performed). Panel F shows the reg-
ulation of bone morphogenetic protein (BMP) signaling by sFrp4. Wnt5a stimulates Bmp2 mRNA expression, which 
was blunted by sFrp4 in MC3T3-E1 cells. The bars show mean values; T bars indicate standard deviations. An aster-
isk indicates P<0.05 for the comparison with control, and a dagger P<0.05 for the comparison with Wnt5a-treated 
cells (three independent experiments were performed). Panel G shows the quantification of Bmp2 mRNA expres-
sion in wild-type and Sfrp4-null calvarial osteoblasts and bone marrow–derived osteoblasts. Sfrp4 deletion affects 
BMP signaling only in calvarial osteoblasts. The bars show mean values; T bars indicate standard deviations. An 
 asterisk indicates P<0.05 for the comparison with wild-type calvarial osteoblasts (three independent experiments 
were performed). In Panels E, F, and G, fold differences in mRNA expression relative to that in wild-type cells were 
calculated as described by Livak and Schmittgen.18 Panel H shows the effects of Sfrp4 deletion on Smad1, Smad5, 
and Smad8 phosphorylation, which occurs only in calvarial osteoblasts. We measured fold differences in protein 
levels by normalizing to Smad1 and dividing the normalized protein level by the mean normalized level in wild-type 
cells; values are expressed as means (±SD). An asterisk indicates P<0.05 for the comparison with wild type (three to 
five independent experiments were performed). Actin was used as a loading control. Panel I shows representative 
histologic features of von Kossa–stained tibiae of 3-week-old wild-type and heterozygous mice after vehicle (phos-
phate-buffered saline) or RAP-661 treatment. Blocking BMP signaling through RAP-661 treatment increases cortical 
thickness in heterozygous mice (five mice were analyzed in each group). Panel J shows representative images of 
von Kossa–stained tibiae of wild-type and Sfrp4-null male mice treated with a sclerostin-neutralizing antibody  
(25 mg per kilogram) or vehicle (phosphate-buffered saline) (three to five mice were analyzed in each group). 
Blocking sclerostin increases cortical thickness in sFrp4-null mice.
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plementary Appendix).19,20 This effect of sFrp4 
was blocked by Jnk inhibitors, whereas Wnt3a, a 
classic canonical Wnt ligand, did not alter the 
activation of the Id–luc reporter gene; this con-
firms that activation of BMP signaling depends 
on the noncanonical branch of Wnt signaling. 
Thus, noncanonical Wnt signaling activates the 
BMP pathway, and sFrp4 inhibits this activation. 
Sfrp4 deficiency is thus expected to result in en-
hanced BMP signaling. Accordingly, expression 
of Bmp2 and of its target gene Id2, as well as 
phosphorylation of Smad1, Smad5, and Smad8, 
were increased in calvarial osteoblasts derived 
from Sfrp4-null mice but not in bone marrow–
derived osteoblasts derived from Sfrp4-null mice 
(Fig. 2H, and Fig. S6C and S6D in the Supple-
mentary Appendix), a finding that supports the 
hypothesis of compartment-specific effects.
Both canonical and noncanonical Wnt signal-
ing cascades also affect osteoclastogenesis and 
bone resorption.9,26-30 In Sfrp4-null mice, the num-
ber of osteoclasts was normal in trabecular bone 
(Table S3 in the Supplementary Appendix) but 
significantly increased along the diaphyseal en-
docortical surface (Fig. S7A in the Supplemen-
tary Appendix). In growing (8-day-old) Sfrp4-null 
mice, the number of osteoclasts along the peri-
osteum was reduced, although not significantly 
(mean [±SE], 2.0±0.3 osteoclasts per periosteal 
perimeter in Sfrp4-null mice vs. 2.4±0.3 osteoclasts 
per periosteal perimeter in wild-type mice; six 
mice per genotype were analyzed), and was consis-
tently increased along the endosteum (6.3±0.8 
osteoclasts per endosteal perimeter in Sfrp4-null 
mice vs. 4.7±0.7 osteoclasts per endosteal perim-
eter in wild-type mice; six mice per genotype 
were analyzed), which may explain the abnormal 
shape and metaphyseal expansion. Together with 
the decreased cortical-bone formation (Fig. S5 in 
the Supplementary Appendix), the increase in 
endocortical bone resorption would be expected 
to contribute to the thinning of cortical bone in 
Sfrp4-null adult mice. Increased osteoclastogen-
esis is consistent with an increase in the ratio of 
Rankl expression to Opg expression (Fig. S7B in 
the Supplementary Appendix). These findings 
show that sFrp4 acts on osteoblasts to suppress 
endocortical osteoclastogenesis by binding to 
noncanonical Wnts (such as Wnt5a) and prevent-
ing activation of BMP signaling in the cortex.
Reversing the Effects of Sfrp4 Deficiency
We therefore used RAP-661 to inhibit the BMP 
pathway in vivo.31 Pharmacologic inhibition of the 
BMP pathway increased cortical-bone thickness 
in wild-type mice and, in mice that were hetero-
zygous for an Sfrp4 mutation, restored the corti-
cal-bone mass to the level found in vehicle-treated 
wild-type mice (Fig. 2I), while further increasing 
the mass of trabecular bone. In addition, RAP-661 
treatment significantly improved the thickness 
and bone mineral density of calvarial bones of 
heterozygous mice. When administered from an 
early age, this treatment led to an improved 
bone shape, partially reversing the bone-model-
ing defect (Fig. 2I). We observed a similar effect 
on the bone mineral density of the tibia mid-
shaft cortical region. The finding that treatment 
with RAP-661 reduced the endogenous expres-
sion of sclerostin both in wild-type mice and in 
heterozygous mice suggested the possibility of 
using a sclerostin-neutralizing antibody to block 
the effects of sclerostin directly.31-33 Inactivation 
of sclerostin in vivo restored the cortical bone 
thickness in Sfrp4-null mice and significantly re-
duced bone diameter (Fig. 2J). Additional pharma-
cologic data are available in Figure S8 and Tables 
S4 and S5 in the Supplementary Appendix.
Discussion
Although cortical-bone fragility is a major con-
tributor to osteoporotic nonvertebral fractures, 
little is known about the specific regulation of 
cortical-bone thickness and density. Moreover, 
current antiosteoporosis therapies have a greater 
effect on trabecular bone than on cortical bone; 
relative changes in trabecular-bone mass in re-
sponse to treatment and as measured by DXA, 
and thereby the reduction of the risk of vertebral 
fractures, are of greater magnitude than are those 
of cortical-bone and nonvertebral fractures. We 
explored the mechanisms that cause Pyle’s dis-
ease, a genetic disorder that is characterized by 
cortical-bone fragility, limb deformity, and frac-
tures, in an effort to understand the mechanisms 
by which cortical-bone homeostasis is regulated. 
In previous studies, genetic bone disorders have 
provided insights into the mechanisms by which 
bone is formed and maintained.9,34,35 On radio-
graphs of patients with Pyle’s disease, the meta-
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physes of tubular bones are widened (their shape 
is similar to that of an oar), the bone cortex is 
either reduced to a barely visible line or absent 
altogether, and the central rarefaction of trabecu-
lar bone tissue is lacking; instead, the metaphyses 
seem to be composed of homogeneous trabecular 
bone.5,6 The radiographic findings in our study 
suggested a vigorous formation of trabecular bone 
and an impairment in the formation or homeo-
stasis of cortical bone, and the abnormal shape 
suggested a failure of the remodeling process 
that occurs in cortical bone during growth.
The genetic studies provided evidence that re-
cessive mutations in SFRP4 are a cause of Pyle’s 
disease. We therefore explored the cellular mech-
anisms of the abnormal bone architecture in 
Sfrp4-null mice. The mouse model reproduced the 
human phenotype to a remarkable degree. We 
showed that the phenotype was due to the dif-
ferential regulation of Wnt signaling and BMP 
signaling (Fig. S9 in the Supplementary Appen-
dix). Whereas deletion of Sfrp4 activated pre-
dominantly canonical Wnt signaling in trabec-
ular bone, leading to increased trabecular bone 
mass, both canonical and noncanonical Wnt sig-
naling were increased in cortical bone. We went 
on to show that both noncanonical Wnt and BMP 
signaling in cortical bone prevented cortical-bone 
formation and had to be down-regulated by 
sFRP4 to allow for proper cortex thickness and 
strength.
Our results also highlight critical limitations 
of the most commonly used tools for the diagnosis 
and evaluation of skeletal diseases. For example, 
DXA measurements that are widely used to predict 
fractures are often discordant between cortical 
(femur) and trabecular (spine) bone sites, leaving 
clinicians in a quandary about whether to treat. 
This is further illustrated in our study, in which, 
despite the presence of profoundly altered bone 
structure involving increased trabecular bone and 
extremely thin cortexes, neither classic measure-
ments of bone mineral density nor biochemical 
markers were reliable indicators of risk. The de-
creased bone mineral density must reflect the 
very thin cortex, but it fails to indicate whether 
the density of trabecular bone is normal or in-
creased. Similarly, markers of bone formation are 
systemically increased, whereas markers of bone 
resorption are unchanged in these patients, which 
reflects the status of the trabecular bone but not 
of cortical bone. In the future, high-resolution 
quantitative computed tomography and the devel-
opment of cortical-bone markers, such as perios-
tin,36,37 may allow an assessment of these two 
bone compartments, as well as stratification of 
the two bone compartments with respect to risk 
prediction.
In summary, we showed that Pyle’s disease 
was caused by a genetic deficiency in sFRP4, that 
there were differences in the homeostasis of cor-
tical bone versus trabecular bone, and that these 
processes might be specifically modulated by phar-
macologic interventions.
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